Theodore Robert Levin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Theodore Robert Levin has a total of 328 co-authors. Here are the top co-authors by number of shared publications:
- Douglas A. Corley
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
52 shared publications - Ethan A. Halm
Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901
49 shared publications - Beverly B. Green
Kaiser Permanente Washington Health Research Institute, Seattle, Washington
48 shared publications - Jessica Chubak
Kaiser Permanente Washington Health Research Institute 1 , Seattle, Washington
38 shared publications - Joanne E. Schottinger
Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health System Sciences, Pasadena, California
37 shared publications - Rebecca A. Ziebell
Kaiser Permanente Washington Health Research Institute, Seattle, Washington
37 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by SAGE Publications in Population Health Management
Improving Colorectal Cancer Screening and Follow-up: Results of a Multi-Organization Quality Improvement Collaborative
Colorectal cancer (CRC) screening rates in the United States remain below national targets, and follow-up after abnormal stool-based testing is frequently incomplete. This study evaluated changes in CRC screening rates, age-based screening disparities, and 90-day follow-up colonoscopy completion among health care organizations participating in a national quality improvement learning collaborative. Using a mixed-methods, pre-test post-test design, 18 health care organizations serving approximately 3.9 million patients aged 45–75 years reported quarterly aggregate data from the third quarter of 2023 through the first quarter of 2025. Up-to-date (UTD) screening rates and 90-day follow-up colonoscopy completion after abnormal non-colonoscopy results were stratified by age group (45–49, 50–64, and 65–75 years). Group averages and within-organization changes were assessed using chi-square tests and paired t- tests, and qualitative implementation data were analyzed using the Consolidated Framework for Implementation Research. The group average UTD screening rate increased from 61.3% to 66.2%, a 4.9-percentage-point improvement ( P < 0.001), corresponding to an estimated 133,538 additional patients screened. Ninety-day follow-up colonoscopy completion increased from 36.2% to 42.9% ( P = 0.005). The screening gap between patients aged 45–49 years and those aged 65–75 years narrowed from 35.7 to 26.3 percentage points ( P < 0.001). High-impact implementation strategies included readiness assessment, facilitation, data infrastructure development, coalition-building, and performance feedback. Participation in a structured national learning collaborative was associated with meaningful improvements in screening, follow-up, and equity across diverse organizations, supporting collaborative, data-driven approaches to advancing preventive care in population health management. Together, these findings constitute statistically meaningful results across the full screening continuum.
- 30 September 2026
- Published by SAGE Publications in Population Health Management
Open AccessImproving Colorectal Cancer Screening and Follow-up: Results of a Multi-Organization Quality Improvement Collaborative
Colorectal cancer (CRC) screening rates in the United States remain below national targets, and follow-up after abnormal stool-based testing is frequently incomplete. This study evaluated changes in CRC screening rates, age-based screening disparities, and 90-day follow-up colonoscopy completion among health care organizations participating in a national quality improvement learning collaborative. Using a mixed-methods, pre-test post-test design, 18 health care organizations serving approximately 3.9 million patients aged 45–75 years reported quarterly aggregate data from the third quarter of 2023 through the first quarter of 2025. Up-to-date (UTD) screening rates and 90-day follow-up colonoscopy completion after abnormal non-colonoscopy results were stratified by age group (45–49, 50–64, and 65–75 years). Group averages and within-organization changes were assessed using chi-square tests and paired t- tests, and qualitative implementation data were analyzed using the Consolidated Framework for Implementation Research. The group average UTD screening rate increased from 61.3% to 66.2%, a 4.9-percentage-point improvement ( P < 0.001), corresponding to an estimated 133,538 additional patients screened. Ninety-day follow-up colonoscopy completion increased from 36.2% to 42.9% ( P = 0.005). The screening gap between patients aged 45–49 years and those aged 65–75 years narrowed from 35.7 to 26.3 percentage points ( P < 0.001). High-impact implementation strategies included readiness assessment, facilitation, data infrastructure development, coalition-building, and performance feedback. Participation in a structured national learning collaborative was associated with meaningful improvements in screening, follow-up, and equity across diverse organizations, supporting collaborative, data-driven approaches to advancing preventive care in population health management. Together, these findings constitute statistically meaningful results across the full screening continuum.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1. from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Study flow diagram. This figure shows the steps used to identify eligible patients with a diagnostic first colonoscopy at ages 42-49 years in three healthcare systems from 2012 to 2020.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1. from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Study flow diagram. This figure shows the steps used to identify eligible patients with a diagnostic first colonoscopy at ages 42-49 years in three healthcare systems from 2012 to 2020.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Positive predictive value (PPV) point estimates (dot) and 95% confidence interval (CI) (bar) of symptom combinations for colorectal cancer.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Positive predictive value (PPV) point estimates (dot) and 95% confidence interval (CI) (bar) of symptom combinations for colorectal cancer.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Background:Diagnosing colorectal cancer in people below age 50 relies largely on the evaluation of symptoms despite recent recommendations to initiate screening at age 45. There is limited information on the positive predictive value (PPV) of symptoms as indicators of early-onset colorectal cancer. Methods:We identified patients aged 42 to 49 years in three community-based health systems between 2012 and 2020 whose first recorded colonoscopy had a diagnostic indication, with symptoms present in the two years before the colonoscopy. We computed the PPV for colorectal cancer by each individual symptom, combinations of the three most common symptoms, and combinations of the three symptoms with the highest PPVs and computed 95% confidence intervals (CI). We also evaluated the PPV of recent symptoms stratified according to the timing of onset and estimated the PPV of symptoms when followed by positive or negative fecal testing. Results:The study included 28,198 patients. The PPV for specific symptoms, with or without other symptoms, was 2.4% (95% CI, 2.2%–2.7%) for blood loss and 4.5% (95% CI, 3.3%–5.9%) for positive fecal testing. Pairwise and three-way combinations of blood loss, diarrhea, and abdominal mass had PPV point estimates for colorectal cancer above 3%. Conclusions:Our study suggests that specific symptoms and combinations may identify patients with a ≥3% prevalence of colorectal cancer in those aged 42 to 49 and that fecal testing results may further identify patients with a higher probability of colorectal cancer. Impact:Future research is needed to develop high PPV strategies for identifying early-onset colorectal cancer without compromising sensitivity.See related In the Spotlight, p. 1233
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Background:Diagnosing colorectal cancer in people below age 50 relies largely on the evaluation of symptoms despite recent recommendations to initiate screening at age 45. There is limited information on the positive predictive value (PPV) of symptoms as indicators of early-onset colorectal cancer. Methods:We identified patients aged 42 to 49 years in three community-based health systems between 2012 and 2020 whose first recorded colonoscopy had a diagnostic indication, with symptoms present in the two years before the colonoscopy. We computed the PPV for colorectal cancer by each individual symptom, combinations of the three most common symptoms, and combinations of the three symptoms with the highest PPVs and computed 95% confidence intervals (CI). We also evaluated the PPV of recent symptoms stratified according to the timing of onset and estimated the PPV of symptoms when followed by positive or negative fecal testing. Results:The study included 28,198 patients. The PPV for specific symptoms, with or without other symptoms, was 2.4% (95% CI, 2.2%–2.7%) for blood loss and 4.5% (95% CI, 3.3%–5.9%) for positive fecal testing. Pairwise and three-way combinations of blood loss, diarrhea, and abdominal mass had PPV point estimates for colorectal cancer above 3%. Conclusions:Our study suggests that specific symptoms and combinations may identify patients with a ≥3% prevalence of colorectal cancer in those aged 42 to 49 and that fecal testing results may further identify patients with a higher probability of colorectal cancer. Impact:Future research is needed to develop high PPV strategies for identifying early-onset colorectal cancer without compromising sensitivity.See related In the Spotlight, p. 1233
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Mats and Methods from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Codes used to identify symptoms.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Mats and Methods from Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer
Codes used to identify symptoms.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Figure S-1 illustrates selection of eligible study population from PRECISE cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Figure S-1 illustrates selection of eligible study population from PRECISE cohort.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-2 displays cumulative risk of death from other causes (competing risk to CRC mortality estimates#), stratified by patient characteristics at index date.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-2 displays cumulative risk of death from other causes (competing risk to CRC mortality estimates#), stratified by patient characteristics at index date.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-1 shows characteristics of screen-eligible patients aged 76-85 years at index date, stratified by healthcare system.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-1 shows characteristics of screen-eligible patients aged 76-85 years at index date, stratified by healthcare system.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Background: Colorectal cancer (CRC) screening is universally recommended for adults ages 45-75 years. Noninvasive fecal occult blood tests are effective screening tests recommended by guidelines. However, empirical evidence to inform older adults’ decisions about whether to continue screening is sparse, especially for individuals with prior screening. Methods: This study used a retrospective cohort of older adults at three Kaiser Permanente integrated healthcare systems (Northern California, Southern California, Washington) and Parkland Health (Dallas, Texas). Beginning one year following a negative stool-based screening test, cumulative risks of CRC incidence, CRC mortality (accounting for deaths from other causes), and non-CRC mortality were estimated. Results: Cumulative incidence of CRC in screen-eligible adults aged 76-85 with a negative fecal occult blood test one year ago (N=118,269) was 0.23% (95% confidence interval [CI]: 0.20-0.26%) after two years and 1.21% (95% CI:1.13-1.30%) after eight years. Cumulative CRC mortality was 0.03% (95% CI: 0.02-0.04%) after two years and 0.33% (95% CI: 0.28-0.39%) after eight years. Cumulative risk of death from non-CRC causes was 4.81% (95% CI: 4.68-4.96%) after two years and 28.40% (95% CI: 27.95-28.85%) after eight years. Conclusion: Among 76-85 year-olds with a recent negative stool-based test, cumulative CRC incidence and mortality estimates were low, especially within two years; death from other causes was over 100 times more likely than death from CRC. Impact: These findings of low absolute CRC risk, and comparatively higher risk of death from other causes, can inform decision-making regarding whether and when to continue CRC screening beyond age 75 among screen-eligible adults.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Background: Colorectal cancer (CRC) screening is universally recommended for adults ages 45-75 years. Noninvasive fecal occult blood tests are effective screening tests recommended by guidelines. However, empirical evidence to inform older adults’ decisions about whether to continue screening is sparse, especially for individuals with prior screening. Methods: This study used a retrospective cohort of older adults at three Kaiser Permanente integrated healthcare systems (Northern California, Southern California, Washington) and Parkland Health (Dallas, Texas). Beginning one year following a negative stool-based screening test, cumulative risks of CRC incidence, CRC mortality (accounting for deaths from other causes), and non-CRC mortality were estimated. Results: Cumulative incidence of CRC in screen-eligible adults aged 76-85 with a negative fecal occult blood test one year ago (N=118,269) was 0.23% (95% confidence interval [CI]: 0.20-0.26%) after two years and 1.21% (95% CI:1.13-1.30%) after eight years. Cumulative CRC mortality was 0.03% (95% CI: 0.02-0.04%) after two years and 0.33% (95% CI: 0.28-0.39%) after eight years. Cumulative risk of death from non-CRC causes was 4.81% (95% CI: 4.68-4.96%) after two years and 28.40% (95% CI: 27.95-28.85%) after eight years. Conclusion: Among 76-85 year-olds with a recent negative stool-based test, cumulative CRC incidence and mortality estimates were low, especially within two years; death from other causes was over 100 times more likely than death from CRC. Impact: These findings of low absolute CRC risk, and comparatively higher risk of death from other causes, can inform decision-making regarding whether and when to continue CRC screening beyond age 75 among screen-eligible adults.
- 22 April 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (9) , 3988-3989
An Evidence-Based Approach to Bridging Healthcare Disparities for Gastroenterological Diseases
- 22 April 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (9) , 3988-3989
An Evidence-Based Approach to Bridging Healthcare Disparities for Gastroenterological Diseases